List view / Grid view
New data shows AstraZeneca’s Imfinzi (durvalumab) achieved an unprecedented five year survival rate of over 40 percent in patients with Stage III non-small cell lung cancer.
In a Phase III trial sugemalimab meaningfully improved progression free survival in patients with stage III non-small cell lung cancer (NSCLC).
Tagrisso (osimertinib) was approved for an indication extension after it reduced risk of death by over 80 percent in certain early-stage non-small cell lung cancer patients.
The conditional marketing authorisation of Retsevmo® (selpercatinib) was based on positive results from the LIBRETTO-001 Phase I/II trial.
In this article, we summarise the trial findings for the European Medicines Agency’s 13 most transformative therapies of 2020.
The approval was based on a Phase III trial in which Libtayo reduced risk of death by 43 percent in non-small cell lung cancer patients with ≥50 percent PD-L1 expression in their tumours.
If the proof-of concept trial of AVA6000 Pro-doxorubicin is successful, it could lead to a pipeline of pro-drug chemotherapies with limited toxicity, say the drug's developers.
Pembrolizumab with pemetrexed and platinum chemotherapy has been recommended by NICE to treat non-squamous, non-small cell lung cancer.
In a Phase II trial, sotorasib was shown to be effective against pre-treated non-small cell lung cancer (NSCLC).
The EMA's human medicines committee has released its results for the December meeting, suggesting which therapies should receive marketing authorisation.
The dose-finding trial will evaluate the safety and activity of UniCAR-T-PSMA in up to 16 patients with advanced relapsed/refractory, PSMA-positive solid tumours.
![Close up view of the Merck logo on the top corner of a glass building [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Merck-aquisition-300x278.jpg)
![Close up view of the Merck logo on the top corner of a glass building [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Merck-aquisition-scaled-e1605009301887.jpg)
The acquisition will strengthen Merck’s oncology pipeline with VLS-101, an investigational antibody-drug conjugate in trials for haematological malignancies and solid tumours.
After three clinical trials showing its efficacy, NICE has recommended Rozlytrek (entrectinib) as treatment for non-small cell lung cancer (NSCLC).
CYRAMZA in combination with erlotinib was approved as a first-line treatment for metastatic EGFR-mutated non-small cell lung cancer.
The FDA has approved Tabrecta (capmatinib) for patients with metastatic non-small cell lung cancer whose tumours have a mutation that leads to MET exon 14 skipping.
